Abstract:Purpose Sirtuin7 (SIRT7), as a member of the sirtuin and NAD + -dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein–protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling. Methods USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student’s t test (two-tailed unpaired) and χ 2 test. Results We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer. Conclusion Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.

A crucial role of SUMOylation in modulating Sirt6 deacetylation of H3 at lysine 56 and its tumor suppressive activity

SUMOylation is Essential for Sirt2 Tumor-Suppressor Function in Neuroblastoma

SUMO protease SENP1 deSUMOylates and stabilizes c-Myc

SUMOylation of Large Tumor Suppressor 1 at Lys751 Attenuates Its Kinase Activity and Tumor-Suppressor Functions

A Chemical Biology Approach to Reveal Sirt6-targeted Histone H3 Sites in Nucleosomes.

SUMOylation Activates Large Tumour Suppressor 1 to Maintain the Tissue Homeostasis During Hippo Signalling

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

SUMOylation Homeostasis in Tumorigenesis

Data from Akt SUMOylation Regulates Cell Proliferation and Tumorigenesis

SUMOylation of Csk Negatively Modulates its Tumor Suppressor Function.

Roles of SUMOylation and De-Sumoylation in Carcinogenesis

Mammalian SIRT6 Represses Invasive Cancer Cell Phenotypes through ATP Citrate Lyase (ACLY)-Dependent Histone Acetylation

Dysregulation of SIRT3 SUMOylation Confers AML Chemoresistance Via Controlling HES1-Dependent Fatty Acid Oxidation.

MOF-mediated Acetylation of SIRT6 Disrupts SIRT6-FOXA2 Interaction and Represses SIRT6 Tumor-Suppressive Function by Upregulating ZEB2 in NSCLC.

Putative Role of Sumoylation in Controlling the Activity of Deubiquitinating Enzymes in Cancer

SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs

The Emerging Roles of SUMOylation in the Tumor Microenvironment and Therapeutic Implications

SUMO and the robustness of cancer

A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis.

Function of SIRT6 in tumor initiation and progression